A community of 30,000 US Transcriptionist serving Medical Transcription Industry
patient considered at high recurrence risk for breast cancer, and I would recommend combination chemotherapy utilizing s/l dose-stent Adriamycin, Cytoxan as well as s/l dose-stent Taxol. Does anyone know what this might be. (Sorry I posted this to the message board earlier - wrong place.) Thx